{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:41:31Z","timestamp":1770781291657,"version":"3.50.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Recent studies have shown that mineralocorticoid receptor antagonists (MRAs) can decrease mortality in patients with heart failure; however, the application of MRAs in current clinical practice is limited because of adverse effects such as hyperkalemia that occur with treatment. Therefore, this meta-analysis used the number needed to treat (NNT) to assess the efficacy and safety of MRAs in patients with chronic heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We meta-analysed randomized controlled trials (RCTs) which contrasted the impacts of MRAs with placebo. As of March 2023, all articles are published in English. The primary outcome was major adverse cardiovascular events (MACE), and secondary outcomes included all-cause mortality, cardiovascular death, myocardial infarction (MI), stroke, and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We incorporated seven studies with a total of 9,056 patients, 4,512 of whom received MRAs and 4,544 of whom received a placebo, with a mean follow-up period of 2.1 years. MACE, all-cause mortality, and cardiovascular mortality were all reduced by MRAs, with corresponding numbers needed to treat for benefit (NNTB) of 37, 28, and 34; as well as no impact on MI or stroke. MRAs increased the incidence of hyperkalemia and gynecomastia, with the corresponding mean number needed to treat for harm (NNTH) of 18 and 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study showed that enabling one patient with HF to avoid MACE required treating 37 patients with MRAs for 2.1 years. MRAs reduce MACE, all-cause mortality, and cardiovascular death; however, they increase the risk of hyperkalemia and gynecomastia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1236008","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T16:03:25Z","timestamp":1699286605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat"],"prefix":"10.3389","volume":"10","author":[{"given":"Chang","family":"Geng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Cheng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-fen","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Bao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40256-019-00325-9","article-title":"Cardiovascular protection with anti-hyperglycemic agents","volume":"19","author":"Deedwania","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 Aha\/Acc\/Hfsa guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1253\/circj.CJ-20-0947","article-title":"Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese registry of acute decompensated heart failure (jroadhf)","volume":"85","author":"Ide","year":"2021","journal-title":"Circ J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/Mnh.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","volume":"135","author":"Lerma","year":"2023","journal-title":"Postgrad Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","article-title":"Mineralocorticoid antagonism and diabetic kidney disease","volume":"19","author":"Lytvyn","year":"2019","journal-title":"Curr Diab Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","article-title":"Number needed to treat (nnt) in clinical literature: an appraisal","volume":"15","author":"Mendes","year":"2017","journal-title":"BMC Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/pds.3874","article-title":"Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone","volume":"24","author":"Mendes","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1080\/14740338.2016.1217989","article-title":"Testing the usefulness of the number needed to treat to be harmed (nnth) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons","volume":"15","author":"Mendes","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","article-title":"Relative vs. Absolute measures of benefit and risk: What's the difference?","volume":"121","author":"Citrome","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"B16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation","volume":"111","author":"Veroniki","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-emphasis-hf)","volume":"82","author":"Tsutsui","year":"2017","journal-title":"Circ J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (area in-chf study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the eplerenone in mild patients hospitalization and survival study in heart failure (emphasis-hf)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMc1405715","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"371","author":"Dalzell","year":"2014","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cjco.2023.03.001","article-title":"Effects of mineralocorticoid receptor antagonists in early-stage heart failure with preserved ejection fraction","volume":"5","author":"Kagami","year":"2023","journal-title":"CJC Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy","volume":"28","author":"Malgie","year":"2023","journal-title":"Heart Fail Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","article-title":"Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis","volume":"16","author":"Berbenetz","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1710731","DOI":"10.1155\/2021\/1710731","article-title":"Aldosterone blockade in acute myocardial infarction: a systematic review and meta-analysis","volume":"2021","author":"Chen","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. Eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ehf2.14137","article-title":"Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure","volume":"10","author":"Henrysson","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002022","article-title":"Motives, frequency, predictors and outcomes of mra discontinuation in a real-world heart failure population","volume":"9","author":"Jonsson Holmdahl","year":"2022","journal-title":"Open Heart"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2147\/DDDT.S189454","article-title":"Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Drug Des Devel Ther"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1236008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T16:03:27Z","timestamp":1699286607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1236008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2023.1236008"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1236008","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"article-number":"1236008"}}